Tech Company Financing Transactions
Opna Bio Funding Round
Opna Bio, based in San Francisco, secured $38 million from Longitude Capital Management, Northpond Ventures and Menlo Ventures.
Transaction Overview
Company Name
Announced On
11/22/2022
Transaction Type
Venture Equity
Amount
$38,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to develop novel fragile-X mental retardation protein (FMRP) inhibitors in oncology as well as a diverse portfolio of clinical and preclinical oncology programs acquired from Plexxikon Inc.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
600 Gateway Blvd. 100
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Undisclosed
Website
Email Address
Overview
Opna Bio is a clinical stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics. The company was founded to develop drugs aimed at disrupting the actions of an unprecedented new cancer target -- fragile-X mental retardation protein (FMRP), as well as a rich pipeline of validated oncology drugs.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Gideon Bollag
Chief Financial Officer
Stuart Barlow
Chief Medical Officer
Jackie Walling
VP - Administration
Dov Gal
VP - Bus. Development
Reinaldo Diaz
VP - Bus. Development
Gaston Habets
Browse more venture capital transactions:
Prev: 11/21/2022: Wove venture capital transaction
Next: 11/22/2022: Julienne Bruno venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs